SEC Company Response from Scinai Immunotherapeutics Ltd. (SCNI) (CIK 0001611747) (SCNI) — May 6, 2015

Scinai Immunotherapeutics Ltd. (SCNI) (CIK 0001611747)
Date: May 6, 2015 · CIK: 0001611747 · Accession: 0001213900-15-003331

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 333-201283

Date

May 6, 2015

Author

/s/ Ron Babecoff

Form

CORRESP

Company

Scinai Immunotherapeutics Ltd. (SCNI) (CIK 0001611747)

Letter

Attention: Matthew Jones Registration Statement on Form F-1 Filed May 6, 2015 File No. 333-201283

Re: Biondvax Pharmaceuticals Ltd.

Dear Mr. Jones:

BiondVax Pharmaceuticals Ltd. (the “Company”) hereby requests acceleration of the effective date of the above-referenced Registration Statement so that such Registration Statement shall become effective on May 7, 2015, at 5:00 p.m., Eastern Daylight Time, or as soon thereafter as is practicable.

The Company hereby acknowledges that:

● should the Securities and Exchange Commission (the “Commission”) or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;

● the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and

● the Company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

Very truly yours,
/s/ Ron Babecoff

Show Raw Text

CORRESP
1
filename1.htm

May 6, 2015

U.S. Securities and Exchange Commission

100 F Street, N.E.

Washington, D.C. 20549-4561

Attention: Matthew Jones

    Re:
    Biondvax Pharmaceuticals Ltd.

Registration Statement
on Form F-1

Filed May 6, 2015

File No. 333-201283

Dear Mr. Jones:

BiondVax Pharmaceuticals
Ltd. (the “Company”) hereby requests acceleration of the effective date of the above-referenced Registration
Statement so that such Registration Statement shall become effective on May 7, 2015, at 5:00 p.m., Eastern Daylight Time, or as
soon thereafter as is practicable.

The Company hereby acknowledges that:

    ●
    should the Securities and Exchange Commission (the “Commission”) or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;

    ●
    the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and

    ●
    the Company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.

    Very truly yours,

    /s/ Ron Babecoff

    Ron Babecoff

    Chief Executive Officer

SecProbe.io